Sixteen patients were enrolled in a trial comparing the change in FPG and risk of hypoglycemia during 6 weeks of SU monotherapy (glimepiride) and 6 weeks of glucagon-like peptide-1 receptor agonist (GLP1RA) monotherapy (liraglutide) with a 1-week washout between medications27. Here, GLP1R is linked to Hypoglycemia.